← Back to Screener
Fulcrum Therapeutics, Inc. Common Stock (FULC)
Price$7.99
Favorite Metrics
Price vs S&P 500 (26W)-18.32%
Price vs S&P 500 (4W)13.40%
Market Capitalization$549.45M
All Metrics
Book Value / Share (Quarterly)$5.24
P/TBV (Annual)1.29x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)61.03%
Cash Flow / Share (Quarterly)$-0.91
Price vs S&P 500 (YTD)-29.70%
Net Profit Margin (TTM)8.13%
EPS (TTM)$-0.90
10-Day Avg Trading Volume0.79M
EPS Excl Extra (TTM)$-0.90
EPS (Annual)$-1.18
ROI (Annual)-21.46%
Net Profit Margin (5Y Avg)-1288.02%
Cash / Share (Quarterly)$5.29
ROA (Last FY)-20.44%
EBITD / Share (TTM)$-0.88
ROE (5Y Avg)-32.06%
Operating Margin (TTM)-3.60%
Cash Flow / Share (Annual)$-0.91
P/B Ratio1.57x
P/B Ratio (Quarterly)2.14x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)4.31x
ROA (TTM)-21.19%
EPS Incl Extra (Annual)$-1.18
Current Ratio (Annual)27.40x
Quick Ratio (Quarterly)27.08x
3-Month Avg Trading Volume1.37M
52-Week Price Return182.53%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.13
P/S Ratio (Annual)6.87x
Asset Turnover (Annual)0.31x
52-Week High$15.74
Operating Margin (5Y Avg)-1396.58%
EPS Excl Extra (Annual)$-1.18
CapEx CAGR (5Y)-25.19%
Tangible BV CAGR (5Y)172.58%
26-Week Price Return-14.33%
Quick Ratio (Annual)27.08x
13-Week Price Return-13.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)27.40x
Enterprise Value$351.919
Asset Turnover (TTM)0.29x
Book Value / Share Growth (5Y)8.97%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-12.16%
Cash / Share (Annual)$5.29
3-Month Return Std Dev77.16%
Net Income / Employee (TTM)$-1
ROE (Last FY)-21.46%
EPS Basic Excl Extra (Annual)$-1.18
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.90
Receivables Turnover (Annual)0.00x
ROI (TTM)-22.54%
P/S Ratio (TTM)6.73x
Pretax Margin (5Y Avg)-1288.02%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.82
Price vs S&P 500 (52W)152.70%
Year-to-Date Return-27.06%
5-Day Price Return4.30%
EPS Normalized (Annual)$-1.18
ROA (5Y Avg)-28.96%
Net Profit Margin (Annual)-12.16%
Month-to-Date Return7.56%
Cash Flow / Share (TTM)$-1.64
EBITD / Share (Annual)$-1.16
Operating Margin (Annual)-27.37%
ROI (5Y Avg)-32.06%
EPS Basic Excl Extra (TTM)$-0.90
P/TBV (Quarterly)1.00x
P/B Ratio (Annual)2.14x
Pretax Margin (TTM)8.13%
Book Value / Share (Annual)$5.24
Price vs S&P 500 (13W)-13.94%
Beta3.25x
Revenue / Share (TTM)$0.00
ROE (TTM)-22.54%
52-Week Low$2.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.06
4.06
4.06
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FULCFulcrum Therapeutics, Inc. Common Stock | 6.73x | — | — | — | $7.99 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases. Its lead candidate, Pociredir, is an oral drug designed to induce fetal hemoglobin in patients with sickle cell disease; Phase 1b data demonstrated clinically meaningful HbF induction and improvements in hemolysis and anemia markers. The company maintains a pipeline of additional clinical and preclinical programs targeting the root causes of rare genetic disorders.